Despite the CLL-IPI including some laboratory features such as the IGHV mutational status and TP53 alterations, no specific biomarker directly reflecting the kinetics of the CLL clone, independent of the tumor mass, such as the lymphocyte doubling time (LDT), is considered [3,5,6,7]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.